HOME ȸ»ç¼Ò°³ ½ÃÀÛÆäÀÌÁö·Î Áñ°Üã±âÃß°¡ ±âÀÚȸ¿ø½Åû
[¸ð¹ÙÀϸðµå] ·Î±×ÀΠȸ¿ø°¡ÀÔ
2024³â04¿ù25ÀÏthu
±â»çÃÖÁ¾ÆíÁýÀÏ: 2024-04-25 16:38:42
´º½ºÈ¨ > µ¿Á¤
2011³â05¿ù09ÀÏ 00½Ã00ºÐ
±ÛÀÚÅ©±â ±â»ç³»¿ë À̸ÞÀϺ¸³»±â ´º½ºÇÁ¸°Æ®Çϱ⠴º½º½ºÅ©·¦Çϱâ
°Ç±¹´ë ÃÖ¼öºÀ ±³¼ö ¡®¼¼°è Àν¶¸°ÆßÇÁ ÇÐȸ¡¯ ȸÀå ÃëÀÓ
5¿ù 13ÀϺÎÅÍ 3ÀÏ °£ ºÒ°¡¸®¾Æ ¹Ù¸£³ª¿¡¼­ °³ÃÖ

°Ç±¹´ë ÀÇÇÐÀü¹®´ëÇпø ÃÖ¼öºÀ ±³¼ö°¡ ¿À´Â 5¿ù 13ÀϺÎÅÍ 15ÀϱîÁö ºÒ°¡¸®¾ÆÀÇ ¹Ù¸£³ª¿¡¼­ ¿­¸®´Â ‘Á¦1ȸ ¼¼°è Á¦2Çü ´ç´¢º´ Àν¶¸°ÆßÇÁ ÇÐȸ¿¡¼­ ºÒ°¡¸®¾Æ ´ç´¢º´ÇÐȸ ȸÀåÀÎ À̹ٳë¹Ù ´Ù½ºÄ®·Î¹Ù¹Ú»ç¿Í ÇÔ²² °øµ¿È¸ÀåÀ¸·Î ÃëÀÓÇÑ´Ù.

Á¦2Çü ´ç´¢º´¿¡ ´ëÇÑ Àν¶¸°ÆßÇÁ Ä¡·á¸¦ ÁÖ·Î ÇÏ´Â ¼¼°è 20°³±¹ÀÇ ÀÇ»çµéÀÌ ¸ð¿© ⸳ÇÑ ‘¼¼°è Á¦2Çü ´ç´¢º´ Àν¶¸°ÆßÇÁ ÇÐȸ’´Â À̹ø ÇÐȸ¿¡¼­ ‘Á¦2Çü ´ç´¢º´Ä¡·á¿¡ ´ëÇÑ »õ·Î¿î Á¢±Ù(New approaches in the treatment of Type 2 Diabetes mellitus)’À̶ó´Â Á¦¸ñÀ¸·Î Á¦2Çü ´ç´¢º´¿¡ ´ëÇÑ Àν¶¸°ÆßÇÁ Ä¡·á¿Í ±×¿¡ ´ëÇÑ ÀÓ»ó ¿¬±¸ °á°ú¸¦ ¼¼°è °¢±¹ÀÇ ÇÐÀÚµéÀÌ ¹ßÇ¥ÇÏ°Ô µÈ´Ù.

‘Á¦1ȸ ¼¼°è Á¦2Çü ´ç´¢º´ Àν¶¸°ÆßÇÁ ÇÐȸ’¿¡´Â ³ë¸£¿þÀÌ, ½º¿þµ§, ½½·Îº£´Ï¾Æ, ³×´ú¶õµå, ÇÁ¶û½º, ºÒ°¡¸®¾Æ, üÄÚ, Çɶõµå, µ¶ÀÏ, À̽º¶ó¿¤, ÀÌÅ»¸®¾Æ, ¸®Åõ¾Æ´Ï¾Æ, È£ÁÖ, ´ºÁú·£µå, À̶õ, ¹Ì±¹, ÀÌÁýÆ®, Æú¶õµå, »ç¿ìµð, ÅÍÅ° µî 20°³±¹ÀÇ ÇÐÀÚ 300¿© ¸íÀÌ Âü°¡ÇÑ´Ù.

À̹ø ÇÐȸ¿¡¼­´Â ÃÖ¼öºÀ ±³¼ö°¡ ‘Àå±â°£ Àν¶¸° ÆßÇÁ Ä¡·á¿¡ °üÂûµÈ Á¦2Çü ´ç´¢º´ÀÇ Ç÷Àå C-peptide ³óµµÀÇ º¯µ¿(Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy)’ Á¦¸ñÀ¸·Î ±âÁ¶ °­ÀǸ¦ ÇÑ´Ù.

ÀÌ¾î °Ç±¹´ë ³ë¿¬Èñ ±³¼ö°¡ ‘À¯º´±â°£ÀÌ ¿À·¡µÈ Á¦2Çü ´ç´¢º´ ȯÀÚ¿¡¼­ Àå±â°£ Áö¼ÓÀû ÇÇÇÏ Àν¶¸° ÁÖÀÔÄ¡·á¿¡ ÀÇÇÑ Àν¶¸°ºÐºñ Áö¼ö ¹× Àν¶¸° ´ëºñ Àü±¸Àν¶¸° ºñÀ² °³¼±È¿°ú’ Á¦¸ñÀÇ ¿¬±¸³í¹®À» ¹ßÇ¥ÇÑ´Ù.

¶Ç, ¹Ì±¹ ĵ»ç½º´ëÇб³ µ¥À̺ø ·Îºó½¼(David Robinson)±³¼ö, µ¶ÀÏ ºòÅÍ À¯¸£°Õ½º ¹Ú»ç(Victor Jurgens, À¯·´ ´ç´¢ÇÐȸ »óÀÓÀÌ»ç), ³×´ú¶õµå ¶óµåº¸¿ìµå´ëÇб³ ÄÚ³Ú¸®¿ì½º Åà ±³¼ö(Cornelius Tack, úÞÀ¯·´´ç´¢ÇÐȸ ±³À°´ã´çÄÚ½º »óÀÓÀÌ»ç), À̹ٳë¹Ù ´Ù½ºÄ®·Î¹Ù(Ivona Daskalova) ¹Ú»ç, ¼ÒÇÇ¾Æ ±ºÀÇ°ú´ëÇб³ Ä«¸à Ä«³×ÇÁ(Kamen Kanev), ÅäÄí´ÙÀÇ°ú´ëÇÐ ½ºÅ¸ÀÌÄÚÇÁ ±³¼ö(I.Stajkov), ºÒ°¡¸®¾Æ ±¹¸³ ÀÇ°ú´ëÇÐ ºí¶óµµÇÁ(Vladov) ±³¼ö, ÀÌŸ® Æĸ£¸¶ ÀÇ°ú´ëÇб³ ÇÁ¶õü½ºÄÚ µ¥¶Ç·¹(Francesco D'Ettore) ±³¼ö µîµµ °¢°¢ ¿¬±¸ ³í¹®À» ¹ßÇ¥ÇÑ´Ù.

ÃÖ¼öºÀ ±³¼ö´Â “À̹ø ÇÐȸ´Â Á¦2Çü ´ç´¢º´¿¡ ´ëÇÑ Àν¶¸°ÆßÇÁ Ä¡·á¸¦ ÇÏ´Â ¼¼°è °¢±¹ÀÇ ÀÇ»çµéÀÌ Ã³À½À¸·Î ¸ð¿© ÇÐȸ¸¦ °á¼ºÇÑ °ÍÀ¸·Î Çѱ¹ÀÇ °Ç±¹´ëº´¿ø ´ç´¢º´¼¾ÅÍ°¡ ÁÖµµÇÑ °Í”À̶ó¸ç “Àν¶¸°ÆßÇÁ Ä¡·á°¡ ¼¼°èÀûÀ¸·Î È®»êµÇ°í ÀÖ´Ù´Â °ÍÀ» º¸¿©ÁÖ´Â ½Ç·ÊÀÌ°í ¿ì¸®ÀÇ ÀÇ·á ±â¼úÀÌ ¼¼°è¿¡¼­ ÀÎÁ¤¹Þ´Â´Ù´Â °ÍÀ» ½ÇÁõÇÏ´Â °Í”À̶ó°í ¹àÇû´Ù.

ÇÑÆí, ÃÖ¼öºÀ ±³¼ö´Â Áö³­ÇØ 9¿ù ½º¿þµ§ÀÇ ½ºÅåȦ¸§¿¡¼­ ¿­¸° Á¦46Â÷ À¯·´´ç´¢º´ÇÐȸ(EASD)¿¡¼­ ±¸µÎ·Î ¹ßÇ¥ÇÑ ‘Àå±â°£ Àν¶¸° ÆßÇÁ Ä¡·á¿¡ °üÂûµÈ Á¦2Çü ´ç´¢º´ÀÇ Ç÷Àå C-peptide ³óµµÀÇ º¯µ¿(Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy)’À̶ó´Â ³í¹®¿¡¼­ Àν¶¸°ÆßÇÁ Ä¡·á¸¦ ÅëÇØ ÃéÀåÀÇ Àν¶¸° ºÐºñ°¡ Á¤»óÀ¸·Î ȸº¹µÇ°í ´çÈ­Ç÷»ö¼Ò(Hemoglobin A1c)µµ Á¤»óÈ­µÇ´Â °ÍÀ» ¹àÇô³Â´Ù°í ¹ßÇ¥ÇÑ ¹Ù ÀÖ´Ù.   

ÀÌ´Â ÀÌÀü±îÁöÀÇ ´ç´¢º´ Ä¡·á¹æ¹ýÀÎ ½ÄÀÌ¿ä¹ý, ¿îµ¿¿ä¹ý, °æ±¸ Ç÷´ç°­ÇÏÁ¦ º¹¿ë ¹× ÇÏ·ç¿¡ Àν¶¸°À» Çѹø ³»Áö´Â µÎ ¹ø ¸Â´Â °í½ÄÀû Àν¶¸° Ä¡·á ½Ã¿¡´Â ‘ÃéÀå¿¡¼­ÀÇ Àν¶¸° ºÐºñ°¡ Áö¼ÓÀûÀ¸·Î °¨¼ÒµÇ¾î ´ç´¢º´À» Ä¡·áÇصµ °íÇ÷´çÀÌ Áö¼ÓÀûÀ¸·Î ¾ÇÈ­µÇ¾î ´ç´¢º´ÀÇ ÇÕº´ÁõÀÌ ¿Ã ¼ö¹Û¿¡ ¾ø´Ù’´Â ±âÁ¸ÀÇ ´ç´¢º´ Ä¡·á °³³ä°ú´Â Á¤¹Ý´ëµÇ´Â °³³äÀ» µµÃâÇس½ ¿¬±¸ °á°ú·Î¼­, Àü ¼¼°è¿¡¼­ ¸ðÀÎ ¾à 5õ¿© ¸íÀÇ ´ç´¢º´ Àü¹®°¡µé·ÎºÎÅÍ Å« °ü½ÉÀ» À̲ø¾î³½ ¹Ù ÀÖ´Ù. 

Á¦2ȸ ‘¼¼°è Á¦2Çü ´ç´¢º´ ¼¼°è Àν¶¸°ÆßÇÁ ÇÐȸ’´Â ³»³â(2012³â)¿¡ Áß±¹ÀÇ º£ÀÌ¡¿¡¼­ ¿­¸± ¿¹Á¤ÀÌ´Ù.

 

 

°ü·Ã±â»ç°¡ ¾ø½À´Ï´Ù
´º½º½ºÅ©·¦Çϱâ
Á¶ÇöÁø (bktimes@korea.com) ±âÀÚ 
À̱âÀÚÀÇ ´Ù¸¥´º½ºº¸±â
µ¿Á¤¼½¼Ç ¸ñ·ÏÀ¸·Î
¿µ³²´ëÀÇ´ë ÃÖÇüö ±³¼ö, ...
ÇѸ²´ë°­³²¼º½Éº´¿ø ±èÁßÀÏ...
¡®ÀÇÇù È­ÀÌÀÚ ±¹Á¦Çù·ÂƯ...
Ä¥°î°æºÏ´ëº´¿ø ¹Ú°æÇö ±³...
Á߾Ӵ뺴¿ø ÀåÁ¤¼ø ±³¼ö, ...
´ÙÀ½±â»ç : ±¹¸³¾Ï¼¾ÅÍ ¼­È«°ü ¹Ú»ç, Àǻ繮Çлó ½ÃºÎ¹® ¼ö»ó (2011-05-12 00:00:00)
ÀÌÀü±â»ç : ±¹¸³¾Ï¼¾ÅÍ Á¤À¯¼® ¹Ú»ç, ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ Çмú»ó ¼ö»ó (2011-05-08 00:00:00)
º´¿ø°è, "°è...
º´¿ø°è, "°è¹¦³â...
Á¦¾à¡¤°Ç½Ä 12°³...
°Çº¸°ø´Ü, ¼Ò¼Ó±â°ü '¼­¿ï¿ä¾ç...
¼ºÀåÇÏ°íÇ ´ç½Å, "Áö±Ý ´ë¿õ,...
º¸·ÉÁ¦¾à, ¿Ã »ó¹Ý±â '¿µ¾÷Á÷ ...
°Çº¸°ø´Ü, ¿ÃÇØ '°³¹æÇü Á÷°ú ...
°Çº¸°ø´Ü, '¿Ã Á¦3Â÷ °³¹æÇü ...
³í¹®) Visual Impairment and Suicide Risk...  
ȸ»ç¼Ò°³ °³ÀÎÁ¤º¸º¸È£Á¤Ã¥ ÀÌ¿ë¾à°ü À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ ¾Ë¸³´Ï´Ù º¸µµÀÚ·á ±â»çÁ¦º¸ Á¤±â±¸µ¶